27.05.2009 Boehringer Ingelheim and the World Stroke Organization announce partnership in the World Stroke Academy For medical media, outside the US only 15.05.2009 Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009 For medical media, outside the US only 13.05.2009 Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome 08.05.2009 Exelixis and Boehringer Ingelheim enter into collaboration for development of S1P1 receptor agonists in the field of autoimmune diseases 30.04.2009 Outcome of new Mirapexin^®/ Sifrol^® (pramipexole) study set to change treatment of depressive symptoms in Parkinson`s disease For medical media, outside the US only 29.04.2009 New study results support once daily, prolonged release formulation of Mirapexin<sup>®</sup>/ Sifrol<sup>®</sup>(pramipexole) for the treatment of Parkinson`s disease For medical media, outside the US only 28.04.2009 No increased risk of treatment-induced augmentation in Restless Legs Syndrome (RLS) demonstrated in long-term placebo-controlled study with Mirapexin^®/ Sifrol^® (pramipexole) For medical media, outside the US only 21.04.2009 Boehringer Ingelheim maintains its growth path in 2008, again growing faster than the pharmaceutical market - major investments once again in Research and Development - good outlook for further growth in 2009 23.03.2009 The European Porcine-Circovirus-Research-Award honours scientists from Denmark, France and Netherlands 20.03.2009 Boehringer Ingelheim`s novel oral anticoagulant dabigatran etexilate is the frontrunner for stroke prevention in atrial fibrillation: final patient completes treatment in the RE-LY® study, the largest atrial fibrillation outcomes trial to date For medical media, outside the US only